{"filings":[{"id":1636796,"accession_number":"0001493152-26-033172","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-07-14T20:00:33+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic presents corporate presentation to employees; details not available in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation given on July 13, 2026 to employees, directors, officers, and advisors.","No specific financial or operational updates are disclosed in the filing text.","Exhibit 99.1 (Corporate Presentation) was not provided in the appended text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1636797,"accession_number":"0001493152-26-033171","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-07-14T20:00:31+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Oncotelic grants 17,796 RSUs to executives tied to exchange uplisting by June 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["17,796 RSUs granted to directors, officers, employees, and advisors; each RSU convertible into 1,000 common shares via Series A Preferred.","CEO Vuong Trieu receives 2,000 RSUs; CMO Anthony Maida and CBO Saran Saund each receive 1,500; CFO Amit Shah receives 1,500.","RSUs vest only if common stock uplists to a national exchange (e.g., Nasdaq, NYSE) on or before June 30, 2027, plus 6 months service.","If uplisting does not occur by June 30, 2027, all RSUs expire; change in control accelerates full vesting.","Potential dilution: up to 17.8 million common shares if all RSUs vest and Preferred converted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1335557,"accession_number":"0001493152-26-031124","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-06-29T21:15:16+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic enters $178K convertible note financing with Pacific Pier Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $178,410 convertible promissory note with 12% OID and 12% interest, maturing in 1 year.","Conversion price: $0.06/share or 85% of lowest VWAP in prior 10 trading days.","Net proceeds to Oncotelic ~$150,000 after buyer's $7,000 legal fee withholding.","Issued 500,000 commitment shares as additional consideration to Pacific Pier.","Prepayment allowed after 6 months; default interest rate of 16% upon event of default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99640,"accession_number":"0001493152-26-021306","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","2.01","3.02","9.01"],"status":"ready","headline":"Oncotelic completes merger transferring patent portfolio to Lunai for $20M Series B Preferred stock","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Oncotelic contributed patent portfolio to Neurobridge Holdings, which merged into Lunai subsidiary; Oncotelic received 5 Series B shares (stated value $12.5M).","Shares convertible at $1.50/common, but conversion requires stockholder approval; no conversion allowed before approval.","Oncotelic retains perpetual, exclusive, royalty-free license to use the patents except for Biodefense and Alzheimer's fields.","Oncotelic agreed to issue 10% of fully diluted shares to Autotelic upon uplisting in exchange for assets including peptide Y, PTH, insulin formulations.","All transactions completed May 1, 2026; no cash exchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99639,"accession_number":"0001493152-26-016981","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic Therapeutics Reports FY 2025 Net Income of $249M Driven by JV Fair Value Gain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income attributable to Oncotelic was $249.3M in FY 2025, compared to net loss of $4.5M in FY 2024.","Non-cash gain of $365.4M from fair value increase in GMP Bio JV investment, partially offset by $111.6M deferred tax provision.","JV subsidiaries Sapu Bio and Sapu Nano formalized; OT-101 Phase 1 combo trial completed and Phase 2/3 pancreatic cancer enrolling.","Deciparticle nanoparticle platform advancing six candidates; everolimus trial enrolling in Australia, INDs expected for palbociclib and docetaxel in 2026.","PDAOAI AI platform expanded to over 100,000 curated abstracts, contributing to seven peer-reviewed publications in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99638,"accession_number":"0001493152-26-014831","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Oncotelic partners with TechForce Robotics to develop AI-enhanced GMP robotics platform","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Joint development, manufacturing, and licensing agreement signed March 31, 2026.","Combines Oncotelic's proprietary PDAOAI platform with TechForce's robotics hardware.","Platform targets GMP-compliant automated material handling, monitoring, and compliance workflows.","Financial terms not disclosed; revenue sharing and royalties to be negotiated in future agreement.","AI foreground IP owned by Oncotelic; jointly developed IP jointly owned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115761,"accession_number":"0001493152-26-013503","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic subsidiary Sapu Nano unveils Deciparticle platform; two Phase 1 assets at BIO-Europe","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sapu Nano to present Deciparticle platform and clinical pipeline at BIO-Europe Spring 2026 on March 25.","Two lead candidates: Sapu003 (everolimus IV) in Phase 1, Sapu006 (docetaxel) entering Phase 1.","Deciparticle is sub-20 nm nanomedicine for hydrophobic drugs, aiming to improve PK and reduce toxicities.","Sapu Nano seeking strategic partnerships to accelerate development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115760,"accession_number":"0001493152-26-013391","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic subsidiary Sapu Nano to present everolimus tissue-toxicity data at SOT 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Sapu Nano (Oncotelic minority interest) to present everolimus toxicology poster at SOT 2026 in San Diego on Mar 23.","Presentation (#3539, board K692) focuses on tissue concentration-driven effects beyond traditional plasma pharmacokinetics.","Data aims to inform improved delivery strategies for mTOR inhibitors, including IV and nanoparticle formulations.","Oncotelic (OTLC) holds minority stake in Sapu Nano; no financial terms or guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115759,"accession_number":"0001493152-26-004237","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic raises $358.5K via secured convertible note with Mast Hill Fund","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $398,333.33 convertible promissory note (10% OID, 10% interest, 1-year maturity) to Mast Hill Fund for net proceeds of ~$350K after fees.","Note convertible at $0.07/share; also issued 1,422,613 warrants at $0.15/share and 1,600,446 commitment shares.","Note secured against company assets excluding certain JV assets (OT-101, CA4P, Oxi4503, AI technologies).","Proceeds designated for general working capital; prepayment allowed with 3 trading days' notice.","Shares issuable upon conversion/exercise not registered; registration rights agreement filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115758,"accession_number":"0001493152-26-003606","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Oncotelic Therapeutics grants CEO up to 26,512 Series A preferred shares based on capital structure milestones","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Dr. Vuong Trieu receives 4,426 preferred shares (convertible to 4.426M common) for first milestone: converting $2.175M 2023 PPM Notes into 2025 Units.","Remaining 22,086 preferred shares vest upon three milestones: $350K debt from Mast Hill Fund with $45M market cap, conversion of $3.3M Autotelic loans, and repayment of $2.175M notes.","Each preferred share converts into 1,000 common shares; total potential dilution up to 26.512M common shares (approx. 4.99% of outstanding).","Agreement includes accelerated vesting upon termination without cause or change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115757,"accession_number":"0001493152-26-000821","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic lowers CEO milestone threshold from $100M to $45M market cap for stock vesting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment reduces first market cap milestone for CEO Vuong Trieu's restricted stock from $100M to $45M.","Similar amendment with Jefferson Capital Ventures LLC lowers its milestone threshold to $45M.","Company states changes are to support progress including equity line with Mast Hills and uplisting efforts.","Other terms and milestones of the restricted stock agreements remain unchanged.","CEO's preferred stock award is tied to the same reduced milestone; no dilution details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115756,"accession_number":"0001493152-26-000619","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Oncotelic lowers market cap milestone for Jefferson Capital from $100M to $45M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment reduces first milestone threshold in independent contractor agreement from $100M to $45M market cap.","Contractor Jefferson Capital Ventures eligible to earn restricted stock upon achieving new $45M milestone.","Amendment aims to facilitate progress on equity line with Mast Hills, AGP financing, and uplisting.","No other terms of the milestone or ICA were changed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115755,"accession_number":"0001493152-26-000613","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Oncotelic completes Tranche 3 of unit offering, raising $1.1M from 22 investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 44 units under final Tranche 3; each unit includes a $25,000 principal, 12% 2-year convertible note.","Each note convertible into 250,000 shares of Oncotelic at $0.10 or 25,000 EdgePoint shares at $1.00.","Each unit includes 250,000 warrants to purchase Oncotelic stock at $0.12 or EdgePoint warrants at $1.25.","Prior 2023 PPM notes settled; existing warrants extended to two years from final closing.","Registration Rights Agreement executed for shares and warrants issued in the financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132184,"accession_number":"0001493152-25-029634","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Oncotelic closes initial $800K convertible note offering at 12% with warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 32 units at $25,000 each to 21 accredited investors; total $800,000 raised.","Each unit consists of a 2-year 12% note convertible into Oncotelic stock at $0.10/share or EdgePoint AI stock at $1.00/share.","Each unit also includes warrants to buy 250,000 Oncotelic shares at $0.12 or 25,000 EdgePoint warrants at $1.25.","Offering allows up to 500 units ($12.5M); prior 2023 PPM note exchanged as part of deal.","Registration rights granted for shares issuable under the units and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132183,"accession_number":"0001493152-25-028921","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic launches PDAOAI platform and opens TGF-β corpus access","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launched PDAOAI, an evidence-interrogation platform for extracting biological signals from large datasets without training custom LLMs.","Providing open access to a TGF-β literature corpus of over 125,000 PubMed abstracts via a dedicated Discord research channel.","Platform aims to enable researchers to analyze complex biomedical data without proprietary data training."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132182,"accession_number":"0001493152-25-026883","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Oncotelic closes initial 11 units of up to 500-unit offering with 12% notes and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing of 11 units at $25,000 each in best-efforts offering of up to 500 units.","Each unit includes a $25,000 note bearing 12% annual interest, due 2 years after final closing.","Notes convertible into OTLC common at $0.10/share or EdgePoint AI common at $1.00/share.","Each unit includes 250,000 warrants to buy OTLC common at $0.12/share or 25,000 EdgePoint warrants at $1.25/share.","Minimum of 10 units required; funds held in escrow until minimum met; offering exempt under Reg D Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132181,"accession_number":"0001493152-25-018877","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEO Vuong Trieu presented at LD Micro conference on Oct 21; specifics not disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Vuong Trieu presented a corporate presentation at LD Micro in San Diego on October 21, 2025.","Exhibit 99.1 containing the presentation is attached but its content was not reproduced in this filing.","No financial results, clinical updates, or guidance changes were provided in the 8-K text.","This is a procedural 8.01 announcement of an investor presentation; no material operational detail."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148754,"accession_number":"0001641172-25-023189","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic Therapeutics enters consulting agreements with Jefferson Capital and Valor Nation for strategic services","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged Jefferson Capital Ventures and Valor Nation for 18-month consulting and advisory services starting August 6, 2025.","Jefferson receives $20,000/month cash and up to 20,320,930 restricted stock awards tied to milestones: market cap >$100M, $10M equity increase, uplisting.","Valor receives 4,064,586 shares of common stock immediately upon signing.","Jefferson's RSAs vest in thirds per milestone; unvested shares forfeited if milestones not achieved.","Shares issued under Section 4(a)(2) exemption from Securities Act registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148753,"accession_number":"0001641172-25-022361","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic secures $560K convertible note from Mast Hill; enters $25M equity purchase agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued $560,000 convertible promissory note to Mast Hill Fund, 10% OID, 10% interest, convertible at $0.07/share.","Note warrants issued for 2,000,000 shares at $0.15 exercise price; note secured against most company assets.","Also entered $25M equity purchase agreement with Mast Hill; issued warrants for 3,350,000 shares.","Equity purchase price set at 97% of market price or 102% of market alternative price; commitment period up to 24 months.","Proceeds from note for general working capital; registration rights agreements filed for resale of underlying shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184916,"accession_number":"0001641172-25-000537","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic announces successful Phase 1 of OT-101/IL-2 for solid tumors; plans combo studies with checkpoint inhibitors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial (NCT04862767) of OT-101 + IL-2 in advanced solid tumors shows tolerable safety, no unexpected signals.","Based on safety data, Oncotelic plans to advance OT-101 + IL-2 into studies with checkpoint inhibitors (e.g., PD-1 blockers) for lung, melanoma, colorectal cancers.","OT-101 is also in Phase 3 STOP-PC study for pancreatic cancer and has shown activity in gliomas.","CEO Dr. Vuong Trieu presented on TGFβ2's role in immune suppression at SWCR 2025 conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184915,"accession_number":"0001493152-25-000028","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic extends reverse merger deadline with Mosaic ImmunoEngineering to June 30, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Term sheet dated April 26, 2024, originally 90-day term, extended to Dec 31, 2024; now extended to June 30, 2025.","No definitive agreement reached; extension allows continued due diligence and documentation.","Both companies mutually agreed extension is in best interests; transaction remains conditional and not guaranteed.","Extension letter executed December 31, 2024; no other term sheet modifications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237390,"accession_number":"0001493152-24-016839","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic sells necroptosis cancer therapy assets to Mosaic for up to $30M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Mosaic to issue $15M in shares at closing; Oncotelic may earn $15M more in cash/shares based on milestones.","Transaction includes Oncotelic's CA4P clinical-stage necroptosis therapies and AI tech for immunotherapy combos.","Mosaic to fund $2.0-$2.5M annual development budget; Oncotelic to loan short-term operational costs until June 1, 2024.","If Oncotelic cannot help raise $2M for Mosaic, transaction may become reverse merger.","Parties to negotiate definitive agreement; closing subject to customary due diligence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254925,"accession_number":"0001493152-24-004783","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Oncotelic completes $0.5M debt conversion and issues 12 convertible note units","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 12 units each with a $25,000 convertible note (convertible at $0.10/share) and warrants to buy 250,000 shares at $0.12/share.","Converted $500,000 of debt from 4 accredited investors under prior private placement into Subscription Agreements.","Paid $45,000 placement agent fees to JH Darbie & Co., which also earned 13% of warrants issued.","This fourth tranche concludes conversion of all notes from prior private placement; company hopes to raise additional funds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272409,"accession_number":"0001493152-23-038620","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Oncotelic closes 3rd tranche of unit financing, raising $1.05M via convertible notes and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["42 units issued at $25,000 each for aggregate $1.05M; each unit includes a convertible note and 250,000 warrants.","Notes convertible at $0.10/share; warrants exercisable at $0.12/share; placement agent fees of $157,500 paid.","Debt of $1.05M from 27 accredited investors converted into the units under the subscription agreements.","Third tranche of a financing previously reported in July 2023; total units subject to best-efforts placement agent agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289231,"accession_number":"0001493152-23-029903","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic JV Sapu starts registrational Phase 2b/3 trial of OT-101 in pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sapu Bioscience (Oncotelic 45% JV partner) signed master services agreement with Cromos Pharma for OT-101 registrational trial.","Trial: Phase 2b/3 of TGF-β2 antisense OT-101 + FOLFIRINOX vs FOLFIRINOX alone in advanced/metastatic pancreatic cancer.","Multinational trial targeting up to 500 patients across USA, EU, and China.","Oncotelic CEO states TGFβ2 suppression may more than double survival in pancreatic cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289230,"accession_number":"0001493152-23-024401","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Oncotelic closes $1.0M debt-to-equity conversion; issues 40 Units with notes and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Converted $1.0M of debt via private placement of 40 Units to accredited investors.","Each Unit: $25K convertible note (16% interest, 2-yr, $0.10 conversion) and 250K warrants at $0.12/share.","Total offering up to 200 Units ($5M); placement agent JH Darbie, $150K fees paid.","Securities unregistered, exempt under Rule 506(b); Registration Rights Agreement filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310013,"accession_number":"0001493152-23-018380","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Oncotelic adopts new bylaws with advance notice provisions for shareholder proposals.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted new amended and restated bylaws on May 18, 2023.","New bylaws add advance notice requirements for shareholder proposals at meetings or consent solicitations.","Replaces prior bylaws; full text filed as Exhibit 3.2.","No financial or operational changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328703,"accession_number":"0001493152-23-007365","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic publishes study showing TGF-β2 predicts poor survival in DIPG; OT-101 protocol accepted by NIHR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Publication in Cancers shows high intra-tumor TGF-β2 level predicts poor survival in pediatric brainstem cancer (DIPG).","TGFβ1 and TGFβ3 isoforms are also predictive; OT-101 is the only TGFβ2 inhibitor in late clinical development.","Clinical study protocol for OT-101 in pediatric brainstem cancer accepted onto UK NIHR portfolio.","CEO states targeting TGFβ2 could rectify previous clinical failures such as bintrafusp alfa."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328702,"accession_number":"0001493152-23-006509","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oncotelic CMO Fatih Uckun resigns; CRO Seymour Fein assumes CMO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fatih Uckun, MD, PhD, resigned as Chief Medical Officer effective February 28, 2023.","Seymour Fein, MD, currently Chief Regulatory Officer, will take over as CMO.","Fein will continue as CRO while assuming additional CMO responsibilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328701,"accession_number":"0001493152-23-000046","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic details 2023 pipeline: 10+ OT-101 trials, pancreatic & glioma FPI, BARDA award","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At least 10 investigator-initiated OT-101 trials planned in 2023 for NSCLC, pancreatic, melanoma, gliomas.","Phase 2/3 pancreatic cancer trial expected FPI 2023; 55% long-term disease control in prior P001 study.","BARDA awarded maximum EZ-BAA funding for OT-101 long COVID; observational trial starts 2023.","Subsidiary Pet2DAO to launch PDAO token and distribute to shareholders/stakeholders in 2023.","R&D costs reduced >95%, G&A >50% per latest 10Q; new CMO and CRO added."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346368,"accession_number":"0001493152-22-035944","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic presents clinical data confirming TGF-β2 as target for gliomas; OS improvements shown","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduced TGF-β2 increased OS from 9 to 22 mos in pediatric brainstem patients (N=95, p<0.0001).","In glioma patients treated with TMZ, reduced TGF-β2 improved OS from 25 to 94 mos (N=230, p<0.0001).","Similar OS improvement from 25 to 94 mos with radiation therapy (N=293, p<0.0001).","Company states failure of GSK's bintrafusp alfa (TGF-β1 trap) validates focus on TGF-β2 isoform.","Data presented at AACR-JCA Joint Conference Dec 10-14, 2022 in Maui."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362760,"accession_number":"0001493152-22-019381","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic presents Phase 1/2 OT-101 pancreatic cancer data; median OS doubled in patients receiving subsequent chemo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["55% of OT-101-treated pancreatic cancer patients had long-term disease control (21 of 37 pts).","Median OS doubled to 9.3 vs 2.6 months (p<0.0001) for those who received subsequent chemotherapy.","High AUC associated with improved OS: 9.6 vs 2.4 months (p=0.0006).","OT-101 PK dose proportional (p<0.0001).","Presentation from JCA-AACR conference available on company website and YouTube."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382375,"accession_number":"0001493152-22-017864","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic issues $335K convertible note to Blue Lake Partners as part of $1M financing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $335,000 convertible promissory note to Blue Lake Partners, LLC at 12% interest.","Note matures in one year; convertible into common stock at $0.10 per share.","Issued 3,025,000 warrants to purchase common stock at $0.20 per share.","Financing part of cumulative $1M raise via JH Darbie; $605K from Mast Hill in May 2022.","Proceeds for general working capital; not for insider loans or illegal purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382374,"accession_number":"0001493152-22-017439","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic discloses JV IPO target and OT-101 COVID mortality data at BIO2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["JVCo IPO on track for 2023 with anticipated minimum valuation of $200M, range $1-5B.","OT-101 combined with immunotherapies including Keytruda (Merck), Tecentriq (Genentech); in various stages.","OT-101 treatment of high-risk COVID patients reduced mortality from 100% to 50% (p=0.003).","Company presentation at BIO International Convention available on website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382373,"accession_number":"0001493152-22-015862","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic issues $605K convertible note to Mast Hill; uses up to $250K to repay prior debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $605,000 convertible promissory note to Mast Hill Fund, LP at 12% interest, convertible at $0.10 per share.","Also issued 3,025,000 warrants with exercise price of $0.20 per share.","Net gross proceeds to company up to $250,000 used to repay prior notes from Talos and FirstFire.","Finder's fee of 10% of gross proceeds and 10% warrant coverage payable to JH Darbie & Co.","Conversion and warrants could cause significant dilution; maturity one year from issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382372,"accession_number":"0001493152-22-012308","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-05-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Oncotelic appoints CMO Fatih Uckun and CRO Seymour Fein effective May 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fatih Uckun appointed Consulting CMO; $504k/year salary, 70% time commitment.","Seymour Fein appointed Consulting Chief Regulatory Officer; $180k/year, 10% time.","Both to lead OT-101 registration trials for DIPG and pancreatic cancer under joint venture.","Uckun previously CMO at Reven, Ares, Aptevo; Fein has 35+ years and 20+ FDA approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382371,"accession_number":"0001493152-22-009787","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-04-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic forms JV with Dragon Overseas for TGF-beta drug OT-101; Dragon invests ~$27.6M for 55% stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oncotelic contributed global, exclusive, perpetual, royalty-free license of OT-101 IP for 45% ownership in JV.","Dragon Overseas invested ~$27.6M in cash and assets for 55% ownership of the JV.","JV to develop OT-101 for DIPG, pancreatic cancer, glioblastoma; company retains up to $50M from RPD voucher sale.","Oncotelic intends to pursue IPO of JV, citing recent successful TGF-beta IPOs.","JV will assume development costs; Oncotelic will participate via JV equity and voucher proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382370,"accession_number":"0001493152-22-009225","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-04-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Oncotelic forms joint venture with Dragon Overseas; Dragon to invest $27.6M for 55% stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dragon Overseas invests $27.6M in cash and assets for 55% of JV; Oncotelic contributes OT-101 licenses for 45%.","Oncotelic eligible for up to $50M from sale of RPD Priority Review Voucher for OT-101 (DIPG) after marketing approval.","JV to develop TGF-β therapeutics, initially focusing on OT-101 for DIPG, pancreatic cancer, and glioblastoma.","If Series A of ≥$20M not completed by Aug 31, 2022, Dragon's funding drops to $250K/month; licenses revert on termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382369,"accession_number":"0001493152-22-009051","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-04-04T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic issues $0.25M convertible note to Fourth Man, LLC at 12% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Convertible promissory note principal $0.25M, 12% annual interest, matures in one year.","Conversion price fixed at $0.10 per share; also issued 1,250,000 warrants at $0.20 exercise.","Finder's fee to JH Darbie: 10% of gross proceeds plus warrants equal to 10% of amount raised.","Proceeds for general working capital and repayment of certain debt; same terms as November 2021 issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382368,"accession_number":"0001493152-22-008698","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic announces JV agreement signing, press release and 8-K forthcoming","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presented at MedInvest Pharmaceutical and Biotechnology Investor Conference on March 31, 2022.","Company stated a joint venture agreement is being signed; further disclosure via press release and 8-K.","No details on JV partner, terms, or timeline provided in the filing.","Presentation and recording available on company website and YouTube channel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400297,"accession_number":"0001493152-22-004825","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic extends JV term sheet standstill with GMP to March 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended standstill provisions of JV term sheet with Golden Mountain Partners to March 31, 2022.","JV intended to develop Oncotelic's drug portfolio and build a manufacturing facility.","Company previously announced plan to take the JV public via IPO at a future date.","Extension allows additional time to complete the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400296,"accession_number":"0001493152-22-004706","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-02-15T23:59:59+00:00","items":["1.01","2.03","3.02"],"status":"ready","headline":"Oncotelic extends JH Darbie note maturity to Mar 2023; issues 33M warrants at $0.15","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of convertible notes extended from March 31, 2022 to March 31, 2023 with all but one investor agreeing.","Company to issue 33,000,066 Oncotelic warrants at an exercise price of $0.15 per common share.","Each Unit holder receives 333,334 warrants per Unit purchased as consideration for the extension.","Notes were originally issued in July 2020 as part of JH Darbie Financing units."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400295,"accession_number":"0001493152-22-003539","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic launches new OT-101 corporate presentation; JV re-IPO funding on track","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["New corporate presentation deployed Feb 7, 2022, covering OT-101 therapeutic programs.","OT-101 program on track to be fully funded by JV for re-IPO, per filing.","No financial figures or milestones disclosed in the 8-K or attached exhibit.","Presentation attached as Exhibit 99.1 but content not available for review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400294,"accession_number":"0001493152-22-002955","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic issues $0.5M convertible note to Golden Mountain Partners as part of $1.5M funding","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $0.5M unsecured convertible note to Golden Mountain Partners, part of up to $1.5M total in three monthly installments.","Note carries 2% annual interest, matures one year from date, convertible into common stock at closing bid price.","Proceeds to support payroll and clinical development of OT-101.","Note contains standard events of default; prepayment allowed with accrued interest.","Conversion shares unregistered, issued under Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400293,"accession_number":"0001493152-22-002488","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2022-01-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic updates on OT-101 biomarker program pursuing accelerated approval route for solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New corporate presentation highlights OT-101 biomarker program with pembrolizumab in multiple phase 2 trials.","Aims to leverage FDA accelerated approval pathway for TMB-H solid tumors, similar to pembrolizumab's June 2020 approval.","Phase 2 trials target solid tumors with high-TGF signature, using a companion diagnostic assay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419257,"accession_number":"0001493152-21-032413","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2021-12-23T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Oncotelic Therapeutics dismisses Baker Tilly, hires Rose Snyder & Jacobs as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Baker Tilly's reports for FY 2020 and 2019 contained a going-concern emphasis paragraph.","No disagreements or reportable events occurred with Baker Tilly during the relevant periods.","New auditor RSJ was engaged effective December 21, 2021 for FY 2021 audit.","Company did not consult RSJ on any accounting or auditing matters prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419256,"accession_number":"0001493152-21-031598","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2021-12-15T23:59:59+00:00","items":["1.01","8.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic issues $0.75M in convertible notes at $0.07/sh; repays $307.5K Geneva Notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued three convertible notes on Dec 9, 12, 15, 2021 totaling $0.75M gross; part of a $1.25M financing round.","Notes bear 12% interest, mature in one year, convertible at $0.07 per share; prepayment permitted with 3 days' notice.","Proceeds used for working capital, debt repayment, and payroll; restrictions on loans to officers/directors apply.","Fully repaid May and June 2021 Geneva Notes ($203,750 + $103,750) with interest and prepayment penalty.","JH Darbie & Co. receives 10% finder's fee in cash and warrants equal to 10% coverage at conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419255,"accession_number":"0001493152-21-030193","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2021-12-01T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic issues $0.5M in convertible notes at $0.07/share to repay existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued two convertible notes: $0.25M to Talos Victory Fund and $0.25M to Mast Hill Fund.","Notes carry 12% annual interest, mature in one year, convertible at $0.07 per share.","Proceeds used to fully repay May 2021 Geneva Note ($203,750) and June 2021 Geneva Note ($103,750).","Financing round aims for up to $1.0M; first two tranches total $0.5M.","JH Darbie & Co. entitled to 10% cash finder's fee and 10% warrant coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419254,"accession_number":"0001493152-21-029741","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2021-11-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncotelic reports positive Phase 2 COVID-19 data: 3X survival benefit for critical patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety endpoints met; OT-101 was safe in severe/critical COVID-19 patients.","End-of-treatment mortality: 4.5% OT-101 vs 20% placebo.","Viral load knockdown >96% in 89% of OT-101 patients vs 67% placebo.","Overall survival for critical patients: 14 days OT-101 vs 4 days placebo (p<0.0166)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419253,"accession_number":"0001493152-21-029720","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2021-11-24T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Oncotelic reports Q3 net loss of $1.9M; provides JV, license, and clinical updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss: $1.86M (($0.00)/share) vs $1.99M (($0.02)/share) in Q3 2020; operating expenses rose to $1.8M.","Secured $1.5M convertible note from GMP in Sep 2021 plus $0.5M in Oct 2021; JV with GMP for product portfolio at 35% stake.","Exclusive license from Autotelic for patents; milestones up to $50M and 15% royalties on net sales.","OT-101/IL-2 combo safety cohort completed; dose escalation above 140 mg/m² ongoing.","OT-101 COVID-19 trial data locked; showed 4.5% mortality (OT-101) vs 20% placebo and improved overall survival."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-24T23:59:59+00:00|419253"}